Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemangioma Clear all
Recruiting Phase 2 Interventional

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

NCT07104331
View directory record Official record
Conditions
Epithelioid Hemangioendothelioma (EHE)
Interventions
nab-Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 5, 2026, 8:33 AM EDT
Withdrawn Phase 2 Interventional

Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

NCT01408056
View directory record Official record
Conditions
Infantile Hemangiomas
Interventions
Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 8 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

NCT03047980
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Sirolimus
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
3 Years to 31 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Optical Biopsy of Human Skin in Conjunction With Laser Treatment

NCT00540566
View directory record Official record
Conditions
Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevi, Congenital Nevi, Seborrheic Keratosis, Paget's Disease, Dermatofibroma, Kaposi's Sarcoma, Port Wine Stain, Hemangioma, Tattoos, Scleroderma, Burns
Interventions
Optical Biopsy imaging
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 5, 2026, 8:33 AM EDT
Not listed Early Phase 1 Interventional

Topical Simvastatin for Treating Infantile Hemangioma

NCT06273111
View directory record Official record
Conditions
Hemangioma Skin
Interventions
5% simvastatin ointment
Drug
Lead sponsor
Joyce Teng
Other
Eligibility
3 Months to 5 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 5, 2026, 8:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers of CASH

NCT04467489
View directory record Official record
Conditions
Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy
Interventions
observational
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational

Optical Tomographic Imaging of Infantile Hemangiomas

NCT01673971
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
Up to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 5, 2026, 8:33 AM EDT
Terminated Not applicable Interventional

Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)

NCT05298709
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Hyperventilation and CO2 challenge
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational

Direct Injection of Alcohol for the Treatment of Spinal Tumors

NCT00001417
View directory record Official record
Conditions
Hemangioma, Neoplasm Metastasis, Spinal Neoplasm
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

NCT01056341
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Pierre Fabre Dermatology
Industry
Eligibility
35 Days to 150 Days
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Irvine, California • Redwood City, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

NCT02603328
View directory record Official record
Conditions
Cerebral Cavernous Malformation
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Topical Timolol Gel for the Treatment of Infantile Hemangiomas

NCT02145884
View directory record Official record
Conditions
Hemangioma
Interventions
timolol maleate 0.5% gel
Drug
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
7 Days to 6 Months
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Studies to Identify Biomarkers for Sturge-Weber Syndrome

NCT04717427
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Not listed
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 5, 2026, 8:33 AM EDT
Withdrawn Not applicable Interventional

Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery

NCT04344626
View directory record Official record
Conditions
Epilepsy, Focal Cortical Dysplasia, Tuberous Sclerosis, Hemimegalencephaly, Polymicrogyria, Rasmussen Encephalitis, Sturge-Weber Syndrome, Gliosis, Stroke, Tumor, Brain
Interventions
Intra-operative brain tonometry
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

NCT03331250
View directory record Official record
Conditions
Angiosarcoma, Epithelioid Hemangioendothelioma
Interventions
Eribulin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

NCT04947124
View directory record Official record
Conditions
Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
Interventions
QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational

Modifiers of Disease Severity in Cerebral Cavernous Malformations

NCT01764529
View directory record Official record
Conditions
Cavernous Angioma, Familial, Cerebral Cavernous Malformations, Cerebral Cavernous Hemangioma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Influence of MMP on Brain AVM Hemorrhage

NCT00783523
View directory record Official record
Conditions
Arteriovenous Malformations, Cavernous Angiomas, Brain Aneurysms
Interventions
Doxycycline or Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 5, 2026, 8:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hemangioma Growth During the First 6 Months of Life

NCT00911781
View directory record Official record
Conditions
Hemangiomas of Infancy
Interventions
No intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 5 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 1 Interventional

Use of the Atkins Diet for Children With Sturge Weber Syndrome

NCT00639730
View directory record Official record
Conditions
Epilepsy, Sturge Weber Syndrome
Interventions
modified Atkins diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

NCT05495269
View directory record Official record
Conditions
Sturge-Weber Syndrome, Glaucoma, Ocular Hypertension
Interventions
QLS-101 ophthalmic solution, 2.0 %
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years to 19 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 5, 2026, 8:33 AM EDT
Completed Phase 2 Interventional Results available

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

NCT02815995
View directory record Official record
Conditions
Advanced and/or Metastatic Sarcoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 5, 2026, 8:33 AM EDT